Akari Therapeutics Plc (AKTX) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Akari Therapeutics Plc  (NASDAQ: AKTX)


Akari Therapeutics Plc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Akari Therapeutics Plc's ROI in the first quarter of 2026?
Akari Therapeutics Plc recorded a cumulative net loss of $-28 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -88.99%.

Within the Healthcare sector 608 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 3341 to 3487.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 101.45 % 419.16 % - 535.85 % 89.61 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 23 37 31 35 33
Return On Investment (TTM) -88.99 % -50.88 % -45.6 % -48.44 % -79.57 %
AKTX's Overall Ranking # 3487 # 3341 # 3486 # 3094 # 3619
Seq. Investment Change TTM -7.3 % -1.71 % 36.59 % 61.85 % 138.91 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -28 -17 -16 -12 -12

AKTX Company Profile >> Back to AKTX Roi Comparisons >> See Annual AKTX Return On Investment



Return On Investment AKTX's Ranking
Within: No.
Industry # 277
Sector # 609
Overall # 3487

Return On Investment Statistics
High Average Low
-50.76 %
-286.26 %
-1495.98 %
(Sep 30 2025)   (Jun 30 2024)



  News about Akari Therapeutics Plc Return on Investment ROI

Illuminating Pathways PAS-nomacopans Promising Trajectory in the Treatment of Geographic Atrophy Post-Pre-IND FDA Me...

August 19, 2024

Geographic atrophy (GA), a progressive retinal degenerative disorder, represents a significant cause of vision loss in the aging population. The recent pre-Investigational New Drug (pre-IND) meeting between Akari Therapeutics and the U.S. Food and Drug Administration (FDA) marks a pivotal moment for PAS-nomacopan, an investigational drug aimed at mitigating GA. This article delves into the implications of the pre-IND feedback provided by the FDA, outlines the clinical and nonclinical development plans for PAS-nomacopan, and discusses the potential impact of the drug on patient outcomes and the broader landscape of GA treatment. Geographic atrophy is characterized by the localized degeneration of the retinal pigment epithelium and photoreceptor cells, resulting in progressive vision loss. Currently, there are limited therapeutic options available to address this condition, necessitating innovative treatments that target its underlying mechanisms. PAS-nomacopan, a complement inhibitor, has emerged as a promising therapeutic candidate in this arena. This article explores the constructive feedback obtained during the recent pre-IND meeting with the FDA, examining its implications for the drug s development and the future of GA therapeutics.





Financial Statements
Akari Therapeutics Plc's I. Quarter Investments $ 23 Millions AKTX's Balance sheet
Akari Therapeutics Plc's I. Quarter Income $ -14 Millions Quarterly AKTX's Income Statement
AKTX's Income by Division See AKTX's Income by Division


AKTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 43 39 7 15 -2
Y / Y Investment Growth 8.57 % 440.92 % -53.12 % - -
Net Income in Millions -17 -20 -13 -13 -17
Y / Y Net Income Growth - - - - -
Annual Return On Investment -40.61 % -50.44 % -176.81 % -84.58 % -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AKTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AKTX's Competitors
Subscribers only: Roi for Akari Therapeutics Plc's Suppliers
Subscribers only: Return On Investment for AKTX's Customers

Other Ratios
AKTX's Roa AKTX's Inventory Turnover Ratio AKTX's Growth Rates AKTX's Dividend Statistics
AKTX's Profitability Ratios AKTX's Asset Turnover Ratio AKTX's Dividend Growth
AKTX's Roe AKTX's Valuation Ratios AKTX's Financial Strength Ratios AKTX's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI

Date modified: 2026-06-23T19:22:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.